Cerebrospinal fluid and plasma biomarkers for dementia with Lewy bodies

Brain and Nerve

Volumn 64, Issue 5, 2012, Pages 505-513

  Kasuga, Kensaku ^a   Ikeuchi, Takeshi ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NIIGATA UNIVERSITY   (Japan)

Author keywords

synuclein; Cerebrospinal fluid; Dementia with Lewy bodies; DJ I; Enzyme linked immunosorbent assay

Indexed keywords

ALPHA SYNUCLEIN; BIOLOGICAL MARKER;

ALZHEIMER DISEASE; BLOOD LEVEL; CEREBROSPINAL FLUID LEVEL; CLINICAL EXAMINATION; COGNITIVE DEFECT; DIAGNOSTIC ACCURACY; DIFFERENTIAL DIAGNOSIS; DIFFUSE LEWY BODY DISEASE; HISTOPATHOLOGY; HUMAN; PARKINSONISM; REVIEW; VISUAL HALLUCINATION;

ALPHA-SYNUCLEIN; BIOLOGICAL MARKERS; DIAGNOSIS, DIFFERENTIAL; HUMANS; LEWY BODY DISEASE; SALIVA;

EID: 84861759005     PISSN: 18816096     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (71)

1. McKeith IG, Galasko D, Kosaka K, Perry EK, Dickson DW, et al: Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology 47: 1113-1124, 1996 (Pubitemid 26374873)
2. Wada-Isoe K, Uemura Y, Suto Y, Doi K, Imamura K, et al: Prevalence of dementia in the rural island town of Ama-cho, Japan. Neuroepidemiology 32: 101-106, 2009
3. Matsui Y, Tanizaki Y, Arima H, Yonemoto K, Doi Y, et al: Incidence and survival of dementia in a general population of Japanese elderly: the Hisayama study. J Neurol Neurosurg Psychiatry 80: 366-370, 2009
4. McKeith IG, Dickson DW, Lowe J, Emre M, O'Brien JT, et al: Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology 65: 1863-1872, 2005 (Pubitemid 43970103)
5. Merdes AR, Hansen LA, Jeste DV, Galasko D, Hofstetter CR, et al: Influence of Alzheimer pathology on clinical diagnostic accuracy in dementia with Lewy bodies. Neurology 60: 1586-1590, 2003 (Pubitemid 36618082)
6. Kosaka K, Oyanagi S, Matsushita M, Hori A: Presenile dementia with Alzheimer-, Pick- and Lewybody changes. Acta Neuropathol 36: 221-233, 1976
7. Kosaka K, Yoshimura M, Ikeda K, Budka H: Diffuse type of Lewy body disease: progressive dementia with abundant cortical Lewy bodies and senile changes of varying degree-a new disease? Clin Neuropathol 3: 185-192, 1984 (Pubitemid 14015451)
8. Lippa CF, Duda JE, Grossman M, Hurtig HI, Aarsland D, et al: DLB and PDD boundary issues: diagnosis, treatment, molecular pathology, and biomarkers. Neurology 68: 812-819, 2007 (Pubitemid 46568532)
9. Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R, et al: Alpha-synuclein in Lewy bodies. Nature 388: 839-840, 1997
10. Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, Dehejia A, et al: Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 276: 2045-2047, 1997 (Pubitemid 27443610)
11. Gai WP, Power JH, Blumbergs PC, Blessing WW: Multiple-system atrophy: a new alpha-synuclein disease? Lancet 352: 547-548, 1998 (Pubitemid 28372254)
12. Spillantini MG, Crowther RA, Jakes R, Cairns NJ, Lantos PL, et al: Filamentous alpha-synuclein inclusions link multiple system atrophy with Parkinson's disease and dementia with Lewy bodies. Neurosci Lett 251: 205-208, 1998 (Pubitemid 28381082)
13. Wakabayashi K, Yoshimoto M, Tsuji S, Takahashi H: Alpha-synuclein immunoreactivity in glial cytoplasmic inclusions in multiple system atrophy. Neurosci Lett 249: 180-182, 1998 (Pubitemid 28331545)
14. Arima K, Ueda K, Sunohara N, Arakawa K, Hirai S, et al: NACP/alpha-synuclein immunoreactivity in fibrillary components of neuronal and oligodendroglial cytoplasmic inclusions in the pontine nuclei in multiple system atrophy. Acta Neuropathol 96: 439-444, 1998 (Pubitemid 28474750)
15. Spillantini MG, Crowther RA, Jakes R, Hasegawa M, Goedert M: alpha-Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with lewy bodies. Proc Natl Acad Sci U S A 95: 6469-6473, 1998 (Pubitemid 28249037)
16. Singleton AB, Farrer M, Johnson J, Singleton A, Hague S, et al: alpha-Synuclein locus triplication causes Parkinson's disease. Science 302: 841, 2003 (Pubitemid 37339619)
17. Zarranz JJ, Alegre J, Gomez-Esteban JC, Lezcano E, Ros R, et al: The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia. Ann Neurol 55: 164-173, 2004 (Pubitemid 38166992)
18. Vekrellis K, Xilouri M, Emmanouilidou E, Rideout HJ, Stefanis L: Pathological roles of alpha-synuclein in neurological disorders. Lancet Neurol 10: 1015-1025, 2011
19. Fujiwara H, Hasegawa M, Dohmae N, Kawashima A, Masliah E, et al: alpha-Synuclein is phosphorylated in synucleinopathy lesions. Nat Cell Biol 4: 160-164, 2002
20. El-Agnaf OM, Salem SA, Paleologou KE, Cooper LJ, Fullwood NJ, et al: Alpha-synuclein implicated in Parkinson's disease is present in extracellular biological fluids, including human plasma. FASEB J 17: 1945-1947, 2003
21. Lee HJ, Patel S, Lee SJ: Intravesicular localization and exocytosis of alpha-synuclein and its aggregates. J Neurosci 25: 6016-6024, 2005 (Pubitemid 40911433)
22. Emmanouilidou E, Melachroinou K, Roumeliotis T, Garbis SD, Ntzouni M, et al: Cell-produced alpha-synuclein is secreted in a calcium-dependent manner by exosomes and impacts neuronal survival. J Neurosci 30: 6838-6851, 2010
23. Emmanouilidou E, Elenis D, Papasilekas T, Stranjalis G, Gerozissis K, et al: Assessment of alpha-synuclein secretion in mouse and human brain parenchyma. PLoS One 6: e22225, 2011
24. Jakowec MW, Petzinger GM, Sastry S, Donaldson DM, McCormack A, et al: The native form of alpha-synuclein is not found in the cerebrospinal fluid of patients with Parkinson's disease or normal controls. Neurosci Lett 253: 13-16, 1998 (Pubitemid 28417007)
25. Borghi R, Marchese R, Negro A, Marinelli L, Forloni G, et al: Full length alpha-synuclein is present in cerebrospinal fluid from Parkinson's disease and normal subjects. Neurosci Lett 287: 65-67, 2000 (Pubitemid 30332379)
26. Tokuda T, Salem SA, Allsop D, Mizuno T, Nakagawa M, et al: Decreased alpha-synuclein in cerebrospinal fluid of aged individuals and subjects with Parkinson's disease. Biochem Biophys Res Commun 349: 162-166, 2006 (Pubitemid 44331776)
27. Mollenhauer B, Cullen V, Kahn I, Krastins B, Outeiro TF, et al: Direct quantification of CSF alpha-synuclein by ELISA and first cross-sectional study in patients with neurodegeneration. Exp Neurol 213: 315-325, 2008
28. Kasuga K, Tokutake T, Ishikawa A, Uchiyama T, Tokuda T, et al: Differential levels of alpha-synuclein, beta-amyloid42 and tau in CSF between patients with dementia with Lewy bodies and Alzheimer's disease. J Neurol Neurosurg Psychiatry 81: 608-610, 2010
29. Hong Z, Shi M, Chung KA, Quinn JF, Peskind ER, et al: DJ-1 and alpha-synuclein in human cerebrospinal fluid as biomarkers of Parkinson's disease. Brain 133: 713-726, 2010
30. Mollenhauer B, Locascio JJ, Schulz-Schaeffer W, Sixel-Doring F, Trenkwalder C, et al: alpha-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study. Lancet Neurol 10: 230-240, 2011
31. Shi M, Bradner J, Hancock AM, Chung KA, Quinn JF, et al: Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression. Ann Neurol 69: 570-580, 2011
32. Tateno F, Sakakibara R, Kawai T, Kishi M, Murano T: Alpha-synuclein in the Cerebrospinal Fluid Differentiates Synucleinopathies (Parkinson Disease, Dementia With Lewy Bodies, Multiple System Atrophy) From Alzheimer Disease. Alzheimer Dis Assoc Disord, 2011 Oct 26 [Epub ahead of print]
33. Spies PE, Melis RJ, Sjogren MJ, Rikkert MG, Verbeek MM: Cerebrospinal fluid alpha-synuclein does not discriminate between dementia disorders. J Alzheimers Dis 16: 363-369, 2009
34. Ohrfelt A, Grognet P, Andreasen N, Wallin A, Vanmechelen E, et al: Cerebrospinal fluid alpha-synuclein in neurodegenerative disorders-a marker of synapse loss? Neurosci Lett 450: 332-335, 2009
35. Noguchi-Shinohara M, Tokuda T, Yoshita M, Kasai T, Ono K, et al: CSF alpha-synuclein levels in dementia with Lewy bodies and Alzheimer's disease. Brain Res 1251: 1-6, 2009
36. Reesink FE, Lemstra AW, van Dijk KD, Berendse HW, van de Berg WD, et al: CSF alpha-synuclein does not discriminate dementia with Lewy bodies from Alzheimer's disease. J Alzheimers Dis 22: 87-95, 2010
37. Aerts MB, Esselink RA, Abdo WF, Bloem BR, Verbeek MM: CSF alpha-synuclein does not differentiate between parkinsonian disorders. Neurobiol Aging 33: 430, e1-e3, 2012
38. Foulds PG, Yokota O, Thurston A, Davidson Y, Ahmed Z, et al: Post mortem cerebrospinal fluid alpha-synuclein levels are raised in multiple system atrophy and distinguish this from the other alpha-synucleinopathies, Parkinson's disease and Dementia with Lewy bodies. Neurobiol Dis 45: 188-195, 2012
39. Ballard C, Jones EL, Londos E, Minthon L, Francis P, et al: alpha-Synuclein antibodies recognize a protein present at lower levels in the CSF of patients with dementia with Lewy bodies. Int Psychogeriatr 22: 321-327, 2010
40. Barbour R, Kling K, Anderson JP, Banducci K, Cole T, et al: Red blood cells are the major source of alpha-synuclein in blood. Neurodegener Dis 5: 55-59, 2008
41. Bateman RJ, Wen G, Morris JC, Holtzman DM: Fluctuations of CSF amyloid-beta levels: implications for a diagnostic and therapeutic biomarker. Neurology 68: 666-669, 2007 (Pubitemid 46667813)
42. Spies PE, Slats D, Olde Rikkert MG, Tseng J, Claassen JA, et al: CSF alpha-synuclein concentrations do not fluctuate over hours and are not correlated to amyloid beta in humans. Neurosci Lett 504: 336-338, 2011
43. Masliah E, Rockenstein E, Veinbergs I, Sagara Y, Mallory M, et al: beta-amyloid peptides enhance alpha-synuclein accumulation and neuronal deficits in a transgenic mouse model linking Alzheimer's disease and Parkinson's disease. Proc Natl Acad Sci U S A 98: 12245-12250, 2001 (Pubitemid 32959858)
44. Pletnikova O, West N, Lee MK, Rudow GL, Skolasky RL, et al: Abeta deposition is associated with enhanced cortical alpha-synuclein lesions in Lewy body diseases. Neurobiol Aging 26: 1183-1192, 2005 (Pubitemid 40726011)
45. Maetzler W, Stoycheva V, Schmid B, Schulte C, Hauser AK, et al: Neprilysin activity in cerebrospinal fluid is associated with dementia and amyloid-beta42 levels in Lewy body disease. J Alzheimers Dis 22: 933-938, 2010
46. Saido TC, Iwata N: Metabolism of amyloid beta peptide and pathogenesis of Alzheimer's disease. Towards presymptomatic diagnosis, prevention and therapy. Neurosci Res 54: 235-253, 2006 (Pubitemid 43374441)
47. Ikeuchi T, Kakita A, Shiga A, Kasuga K, Kaneko H, et al: Patients homozygous and heterozygous for SNCA duplication in a family with parkinsonism and dementia. Arch Neurol 65: 514-519, 2008 (Pubitemid 351549961)
48. Uchiyama T, Ikeuchi T, Ouchi Y, Sakamoto M, Kasuga K, et al: Prominent psychiatric symptoms and glucose hypometabolism in a family with a SNCA duplication. Neurology 71: 1289-1291, 2008
49. Miller DW, Hague SM, Clarimon J, Baptista M, Gwinn-Hardy K, et al: Alpha-synuclein in blood and brain from familial Parkinson disease with SNCA locus triplication. Neurology 62: 1835-1838, 2004 (Pubitemid 38661745)
50. Adams JR, van Netten H, Schulzer M, Mak E, McKenzie J, et al: PET in LRRK2 mutations: comparison to sporadic Parkinson's disease and evidence for presymptomatic compensation. Brain 128: 2777-2785, 2005 (Pubitemid 41746632)
51. Shi M, Furay AR, Sossi V, Aasly JO, Armaly J, et al: DJ-1 and alphaSYN in LRRK2 CSF do not correlate with striatal dopaminergic function. Neurobiol Aging 2011
52. Sharon R, Bar-Joseph I, Frosch MP, Walsh DM, Hamilton JA, et al: The formation of highly soluble oligomers of alpha-synuclein is regulated by fatty acids and enhanced in Parkinson's disease. Neuron 37: 583-595, 2003 (Pubitemid 36262981)
53. Paleologou KE, Kragh CL, Mann DM, Salem SA, Al-Shami R, et al: Detection of elevated levels of soluble alpha-synuclein oligomers in post-mortem brain extracts from patients with dementia with Lewy bodies. Brain 132: 1093-1101, 2009
54. Tokuda T, Qureshi MM, Ardah MT, Varghese S, Shehab SA, et al: Detection of elevated levels of alpha-synuclein oligomers in CSF from patients with Parkinson disease. Neurology 75: 1766-1772, 2010
55. Desplats P, Lee HJ, Bae EJ, Patrick C, Rockenstein E, et al: Inclusion formation and neuronal cell death through neuron-to-neuron transmission of alpha-synuclein. Proc Natl Acad Sci U S A 106: 13010-13015, 2009
56. Brown DR: Oligomeric alpha-synuclein and its role in neuronal death. IUBMB Life 62: 334-339, 2010
57. El-Agnaf OM, Salem SA, Paleologou KE, Curran MD, Gibson MJ, et al: Detection of oligomeric forms of alpha-synuclein protein in human plasma as a potential biomarker for Parkinson's disease. FASEB J 20: 419-425, 2006 (Pubitemid 44933318)
58. Lee PH, Lee G, Park HJ, Bang OY, Joo IS, et al: The plasma alpha-synuclein levels in patients with Parkinson's disease and multiple system atrophy. J Neural Transm 113: 1435-1439, 2006 (Pubitemid 44435881)
59. Duran R, Barrero FJ, Morales B, Luna JD, Ramirez M, et al: Plasma alpha-synuclein in patients with Parkinson's disease with and without treatment. Mov Disord 25: 489-493, 2010
60. Li QX, Mok SS, Laughton KM, McLean CA, Cappai R, et al: Plasma alpha-synuclein is decreased in subjects with Parkinson's disease. Exp Neurol 204: 583-588, 2007 (Pubitemid 46497045)
61. Shi M, Zabetian CP, Hancock AM, Ginghina C, Hong Z, et al: Significance and confounders of peripheral DJ-1 and alpha-synuclein in Parkinson's disease. Neurosci Lett 480: 78-82, 2010
62. Foulds PG, Mitchell JD, Parker A, Turner R, Green G, et al: Phosphorylated alpha-synuclein can be detected in blood plasma and is potentially a useful biomarker for Parkinson's disease. FASEB J 25: 4127-4137, 2011
63. Laske C, Fallgatter AJ, Stransky E, Hagen K, Berg D, et al: Decreased alpha-synuclein serum levels in patients with Lewy body dementia compared to Alzheimer's disease patients and control subjects. Dement Geriatr Cogn Disord 31: 413-416, 2011
64. Devic I, Hwang H, Edgar JS, Izutsu K, Presland R, et al: Salivary alpha-synuclein and DJ-1: potential biomarkers for Parkinson's disease. Brain 134: e178, 2011
65. Choi J, Sullards MC, Olzmann JA, Rees HD, Weintraub ST, et al: Oxidative damage of DJ-1 is linked to sporadic Parkinson and Alzheimer diseases. J Biol Chem 281: 10816-10824, 2006 (Pubitemid 43855504)
66. Kahle PJ, Waak J, Gasser T: DJ-1 and prevention of oxidative stress in Parkinson's disease and other age-related disorders. Free Radic Biol Med 47: 1354-1361, 2009
67. Bonifati V, Rizzu P, van Baren MJ, Schaap O, Breedveld GJ, et al: Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism. Science 299: 256-259, 2003 (Pubitemid 36131051)
68. Waragai M, Wei J, Fujita M, Nakai M, Ho GJ, et al: Increased level of DJ-1 in the cerebrospinal fluids of sporadic Parkinson's disease. Biochem Biophys Res Commun 345: 967-972, 2006 (Pubitemid 43776502)
69. Waragai M, Nakai M, Wei J, Fujita M, Mizuno H, et al: Plasma levels of DJ-1 as a possible marker for progression of sporadic Parkinson's disease. Neurosci Lett 425: 18-22, 2007 (Pubitemid 47410359)
70. Maita C, Tsuji S, Yabe I, Hamada S, Ogata A, et al: Secretion of DJ-1 into the serum of patients with Parkinson's disease. Neurosci Lett 431: 86-89, 2008
71. Trojanowski JQ, Vandeerstichele H, Korecka M, Clark CM, Aisen PS, et al: Update on the biomarker core of the Alzheimer's Disease Neuroimaging Initiative subjects. Alzheimers Dement 6: 230-238, 2010